40 results
8-K
EX-1.1
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission, retention and legending
8-K
EX-99.3
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
and retention bonuses resulting from pre-existing employment agreements or from approval by Talaris’ board of directors that was paid in cash in connection … with the Merger that were not incurred as of September 30, 2023. As all severance and retention bonuses have been paid by the date hereof
8-K
EX-10.7
f81iunv7zf8882pj7
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
424B3
5foca ye17pfdgz
15 Sep 23
Prospectus supplement
6:31am
S-4/A
jf7 o6cx27uupkwkk
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
4gmvb
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
EX-10.4
1go09xml osargnt1
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
7snvv tzu8ik6
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-2.1
ccwe1jkjv
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am
8-K
EX-10.1
y8o 2a1eb
14 Apr 23
Cost Associated with Exit or Disposal Activities
5:20pm
8-K
7kh9j7wc
14 Apr 23
Cost Associated with Exit or Disposal Activities
5:20pm